Skip to main navigation
Akero
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Our History
    • Leadership
    • Contact
  • Focus
    • Therapeutic Areas
    • Publications & Posters
  • Pipeline
    • Development Pipeline
    • Efruxifermin (EFX)
    • Research Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access Policy
  • Careers
    • Our Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
Select Page
Akero
    • About
      • Our Company
      • Our History
      • Leadership
      • Contact
    • Focus
      • Therapeutic Areas
      • Publications & Posters
    • Pipeline
      • Development Pipeline
      • Efruxifermin (EFX)
      • Research Programs
    • Clinical Trials
      • Clinical Trials Overview
      • Expanded Access Policy
    • Careers
      • Our Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Analyst Coverage
      • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
        • Committee Composition
      • Investor Resources
        • Investor FAQs
        • Investor Email Alerts
        • Contact IR
    • Linked
    • Twitter
Hero-banner

Event Details

Hero-banner

Akero Therapeutics Reports Biopsy Data and Safety/Tolerability for 16-Week Phase 2a BALANCED Study in NASH Patients

Jun 30, 2020 at 4:30 PM EDT

Supporting Materials

View presentation 1.1 MB
  • About
  • Our Company
  • Our History
  • Leadership
  • Contact
  • Focus
  • Therapeutic Areas
  • Publications & Posters
  • Pipeline
  • Development Pipeline
  • Efruxifermin (EFX)
  • Research Programs
  • Clinical Trials
  • Clinical Trials Overview
  • Expanded Access Policy
  • Careers
  • Our Culture
  • Job Opportunities
  • Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Footer logo
©2021 Akero Therapeutics, Inc.
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter